SB128 would change Kentucky law governing health insurance prescription drug cost sharing and rebate treatment. The bill requires, to the extent allowed by federal law, that an insured’s cost sharing for a prescription drug be calculated at the point of sale and that rebates received by insurers, pharmacy benefit managers (PBMs), or other pharmacy benefit administrators be passed through to lower the insured’s cost sharing first, with any remaining rebate value used to reduce premiums. It also bars insurers and PBMs from requiring an insured to pay more at the pharmacy than the drug would cost without coverage, with an exception for drugs that have a generic alternative unless the patient accessed the brand drug through prior authorization, step therapy, or the appeals process.
The bill also adds confidentiality and trade-secret protections for rebate information. It declares product-, manufacturer-, and pharmacy-specific rebate amounts to be trade secrets, limits disclosure, and makes that information exempt from public records laws, while still allowing the insurance commissioner to require reporting for compliance and regulatory purposes. In addition to the main prescription drug provisions, the bill amends several existing health coverage statutes so the new rules apply to limited health service benefit plans, limited health service organizations, the state employee health insurance program, and self-insured plans offered by state postsecondary educational institutions.
For state employee and higher education plans, SB128 incorporates the new prescription drug rebate and cost-sharing rules into those public plans and preserves existing plan requirements. The bill also keeps in place existing provisions on mail-order drugs, hearing aids, autism coverage, amino acid-based formula, special enrollment for pregnant women, and other mandated benefits already tied to those plans. The bill states that it applies only to health plans issued or renewed on or after January 1, 2027, and takes effect on that same date.
The general sentiment in the available record is difficult to gauge because there are no committee transcripts or recorded votes attached to the bill. Based on the text, the measure appears designed to lower out-of-pocket prescription drug costs for insured consumers and redirect rebate savings toward premiums, while also protecting rebate negotiations from public disclosure. The absence of recorded debate or votes means there is no documented support or opposition in the provided materials.
The main points of potential contention are likely to be the rebate pass-through mandate, the prohibition on charging more than the uninsured cash price, and the trade-secret treatment of rebate data. Consumer advocates may favor the cost-sharing protections and rebate pass-through requirements, while insurers, PBMs, and manufacturers may object to the operational burden, pricing constraints, and disclosure limits. Another possible issue is the bill’s interaction with federal law and high-deductible health plans, since the bill expressly defers where federal law would be affected.
SB128 would amend Kentucky insurance and health-plan statutes to require new prescription drug cost-sharing and rebate-pass-through rules for most insured plans, including limited health service plans, state employee coverage, and certain university self-insured plans. It would also create a new trade-secret provision in KRS Chapter 365 protecting rebate amounts from public disclosure, while preserving regulatory access for the Department of Insurance. The bill would affect insurers, PBMs, pharmacy benefit administrators, pharmacies, and insured consumers, and would apply prospectively to plans issued or renewed on or after January 1, 2027.
No committee transcript or vote history is provided, so there is no direct record of debate, amendments, or roll-call support/opposition. From the bill text alone, the measure reads as consumer-cost-focused and prescription-drug affordability oriented, with a parallel emphasis on protecting rebate confidentiality for industry participants. The overall sentiment in the available materials is therefore neutral to favorable toward lowering patient costs, but with likely industry concern over rebate transparency and pricing mandates.
The most notable contention points are the requirement that rebates be used to reduce point-of-sale cost sharing and, if not needed there, to reduce premiums, as well as the prohibition on charging an insured more than the cash price for a drug. Insurers and PBMs may also object to the bill’s limits on how rebate data can be disclosed, even though the bill classifies those amounts as trade secrets and restricts public access. The generic-drug exception, the treatment of high-deductible health plans, and the bill’s application to public employee and university plans are additional areas where implementation and cost impacts could be debated.